Published in Circ Heart Fail on October 15, 2013
Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes (2015) 1.50
Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium. Circ Cardiovasc Qual Outcomes (2015) 0.86
Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Med (2015) 0.80
Interaction between the Kansas City Cardiomyopathy Questionnaire and the Pocock's clinical score in predicting heart failure outcomes. Qual Life Res (2015) 0.75
Sex- and gender-specific research priorities for the emergency management of heart failure and acute arrhythmia: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research Workgroup. Acad Emerg Med (2014) 0.75
Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol (2017) 0.75
INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. Circ Heart Fail (2017) 0.75
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
Cronbach's alpha. BMJ (1997) 13.79
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol (2000) 6.08
Systolic and diastolic heart failure in the community. JAMA (2006) 5.99
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J (2011) 2.97
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Epidemiology of diastolic heart failure. Prog Cardiovasc Dis (2005) 2.59
Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail (2012) 2.53
FDA guidance on patient reported outcomes. BMJ (2010) 2.09
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant (2001) 1.92
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation (2009) 1.82
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation (2011) 1.78
Interpreting statistics in medical literature: a vade mecum for surgeons. J Am Coll Surg (2004) 1.70
Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol (2001) 1.65
The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail (2009) 1.63
Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation (2004) 1.63
Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol (2003) 1.60
The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail (2005) 1.58
Evolving applications for patient-centered health status measures. Circulation (2008) 1.57
Quality of life in patients with advanced heart failure. J Heart Lung Transplant (1992) 1.47
Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res (2011) 1.43
Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail (2012) 1.32
Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation (2003) 1.32
Association of functional and health status measures in heart failure. J Card Fail (2006) 1.25
Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation (2007) 1.24
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail (2006) 1.23
Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. Qual Life Res (2007) 1.09
Quality of life and survival in patients with heart failure. Eur J Heart Fail (2012) 1.03
Summary health status measures in advanced heart failure: relationship to clinical variables and outcome. J Card Fail (2007) 1.02
Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail (2011) 0.97
The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev (2006) 0.96
[The Kansas City Cardiomyopathy Questionnaire (KCCQ) -- a new disease-specific quality of life measure for patients with chronic heart failure]. Psychother Psychosom Med Psychol (2005) 0.95
Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail (2009) 0.94
The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry. Am Heart J (2009) 0.92
Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail (2009) 0.92
Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. Am Heart J (2012) 0.83
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail (2005) 0.80
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail (2009) 0.77
Counting performance with therapies for heart failure: aiming for quality or quantity? Circulation (2010) 0.77
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Serum potassium levels and mortality in acute myocardial infarction. JAMA (2012) 4.09
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA (2010) 3.36
Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA (2008) 3.30
Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med (2009) 3.27
Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med (2013) 3.26
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation (2008) 3.19
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
The concept of risk in comparative-effectiveness research. N Engl J Med (2014) 3.04
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol (2008) 2.89
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J (2005) 2.81
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol (2005) 2.81
Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes (2011) 2.77
Racial differences in survival after in-hospital cardiac arrest. JAMA (2009) 2.65
Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg (2006) 2.62
Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol (2010) 2.62
Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62
Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) (2007) 2.62
Factors associated with racial differences in myocardial infarction outcomes. Ann Intern Med (2009) 2.54
The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol (2012) 2.50
Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol (2010) 2.49
Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation (2004) 2.45
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA (2009) 2.42
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol (2009) 2.40
Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. JAMA (2010) 2.33
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med (2011) 2.29
Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg (2010) 2.23
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. Catheter Cardiovasc Interv (2010) 2.21
Preoperative anxiety as a predictor of mortality and major morbidity in patients aged >70 years undergoing cardiac surgery. Am J Cardiol (2013) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med (2008) 2.16
Disease-specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta-analysis of prospective cohort studies. Eur J Heart Fail (2014) 2.13
Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: a potential mechanism for depressed myocardial function in hibernating myocardium in humans. Circulation (2002) 2.11
American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation (2005) 2.10
Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol (2011) 2.06
Heart failure guidelines, performance measures, and the practice of medicine: mind the gap. J Am Coll Cardiol (2010) 2.06
Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the veterans administration cardiac care follow-up clinical study. Diabetes Care (2013) 2.04
The importance of the conformality, heterogeneity, and gradient indices in evaluating Gamma Knife radiosurgery treatment plans for intracranial meningiomas. Int J Radiat Oncol Biol Phys (2011) 2.03
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv (2009) 2.03
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J (2011) 2.00
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)--evaluating the impact of myocardial infarction on patient outcomes. Am Heart J (2006) 1.98
The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res (2008) 1.94
Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes (2009) 1.89
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89